RxDoctor Payments Data

Anastasia Krosnick

Psychiatric/Mental Health · Hackensack, NJNPI 1629552245

Payments from drug & device makers

$1,511in general payments, 2019–2025

Across 80 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$533
  • AbbVie$394
  • Teva Pharmaceuticals USA, Inc.$219
  • Sunovion Pharmaceuticals Inc.$139
  • Takeda Pharmaceuticals U.S.A., Inc.$48
  • E.r. Squibb & Sons, L.L.C.$36
  • plus $142 from 6 others

What the payments were for

  • Food & beverage$1,39993%
  • Education$1117%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,511 in reported general payments places this provider in the 75th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$19,009
Medicare patients
49
Services billed
279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$89,853
Invega SustennaPaliperidone Palmitate15$46,320
RexultiBrexpiprazole26$37,995
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl24$8,204
Aripiprazole123$4,385
Quetiapine Fumarate386$3,576
Bupropion XlBupropion Hcl126$2,205
Trazodone Hcl299$2,166
Paliperidone ErPaliperidone22$2,125
Olanzapine133$1,933
Duloxetine Hcl101$1,758
Ziprasidone Hcl29$1,380
Clonazepam158$1,260
Olanzapine OdtOlanzapine34$1,232
Escitalopram Oxalate145$1,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$13$89,85312 claims
Otsuka America Pharmaceutical, Inc.Rexulti$533$37,99526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →